Target Complement system
(Unterschied zwischen Versionen)
| Zeile 6: | Zeile 6: | ||
{{tp|p=32417135|t=2020. Complement activation in patients with COVID-19: A novel therapeutic target.|pdf=|usr=008}} | {{tp|p=32417135|t=2020. Complement activation in patients with COVID-19: A novel therapeutic target.|pdf=|usr=008}} | ||
{{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}} | {{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}} | ||
| + | {{tp|p=32430402|t=2020. Could severe COVID-19 be considered a complementopathy?|pdf=|usr=009}} | ||
Version vom 8. Juli 2020, 15:08 Uhr
32360516 ä. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
32329881 2020. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience
32327719 ä. Complement as a target in COVID-19?
| 32271624 2020. Will Complement Inhibition be the New Target in Treating COVID-19 Related Systemic Thrombosis? |
32495372 2020. Terminal complement inhibition dampens the inflammation during COVID-19.
32417135 2020. Complement activation in patients with COVID-19: A novel therapeutic target.
32581810 2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.
32430402 2020. Could severe COVID-19 be considered a complementopathy?
